Company Overview and News

4
Tata Motors supplies ten EVs to Cognizant

2018-07-18 moneycontrol
Tata Motors, today said it supplied ten Tigor Electric Vehicles (EVs) to IT major Cognizant which would deploy them in its city campus as part of its commitment to a sustainable environment. According to a press release from Tata Motors, the automaker has partnered with Volercars, a mobility solutions company that will be delivering this integrated solution with the value added service to Cognizant including on ground operations and fleet management.
TATAPOWER TPCL 500400 500570 TATAMOTORS TTM

0
Tata Power arm to develop 250 MW solar project in Karnataka

2018-07-11 moneycontrol
Tata Power Renewable Energy (TPREL) has bagged an order from Karnataka to develop 250 MW solar project in the state's Tumkur district. The project will be set up at Pavagada Solar Park in Tumkur and the energy will be supplied to the state discoms under a power purchase agreement (PPA) valid for 25 years, Tata Power said in a statement.
TATAPOWER TPCL 500400

0
Tata Power arm to develop 250 MW solar project in Karnataka

2018-07-11 economictimes.indiatimes
Copyright © 2018 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service
TATAPOWER TPCL 500400

4
Podcast | Pick of the day - NCLT okays Tatas#39; bye bye to Cyrus Mistry

2018-07-09 moneycontrol
It appears there is finally some resolution in the eighteen-month-long battle between the Tata Sons and Cyrus Mistry at the National Company Law Tribunal (NCLT). Today, the NCLT dismissed Cyrus Mistry’s plea for his alleged illegal removal from the post of Tata Sons’ Chairman. And that is our Pick of the Day.
500408 TTML TATACOFFEE 500800 BHUSANSTL TTAZF TTQQY BHRQY TATACOMM TTNQY TATACHEM TTAEY 532301 TGBL 500470 532540 TATAINVEST TATASPONGE 501301 500570 BHARTIARTL TATAMOTORS 500770 500055 513010 TGBA TATAMETALI TATAPOWER 513434 532454 TTST TATASTEEL TATLY 532371 TPCL TATAELXSI TCS 500400 500483 TATAGLOBAL TTM

4
NCLT ruling: Tata Motors, Tata Coffee jump 2%, TCS falls over 1%

2018-07-09 thehindubusinessline
Shares of various Tata group companies witnessed a mixed trend after the National Company Law Tribunal (NCLT) dismissed the pleas of Cyrus Mistry against Tata Sons for removing him as Chairman.
TATACOFFEE TATAPOWER TTQQY TTNQY TATACHEM 532301 500470 532540 TTST TATASTEEL TATLY TPCL 500400 TCS 500570 TATAMOTORS 500770 TTM

4
Tata Group stocks rally 1-5% after NCLT rules in Tata Sons#39; favour in Cyrus Mistry case

2018-07-09 moneycontrol
Tata Group stocks gained on Monday after the National Company Law Tribunal ruled in favour of Tata Sons against Cyrus Mistry's plea with regards to his removal as Tata Sons Chairman.
500408 TTML TTQQY TATACOMM TTNQY TATACHEM 500470 532540 TATAINVEST TATASPONGE 501301 500570 TATAMOTORS 500770 513010 TATAMETALI TATAPOWER 513434 TTST TATASTEEL TATLY 532371 TPCL TATAELXSI TCS 500400 500483 TTM

0
Hope flickers for troubled power projects in Gujarat

2018-07-04 economictimes.indiatimes
Share market update: Power stocks mixed, but the sectoral index up on gains in Power Grid, Tata Power
TATAPOWER TPCL 500400

0
Tata Power gains 1% on commissioning 100 MW solar plant in Andhra Pradesh

2018-07-03 moneycontrol
Shares of Tata Power gained 1 percent intraday Tuesday as company's subsidiary Tata Power Renewable Energy commissioned 100 MW solar capacity in Anthapuramu solar park, Andhra Pradesh.
TATAPOWER TPCL 500400

1
Market Live: Sensex gains strength, Nifty reclaims 10,700; Nikkei, Shanghai recover from day#39;s low

2018-07-03 moneycontrol
Market Expert: Dhananjay Sinha, Head of Research, Economist and Strategist, Emkay Global Financial Services told CNBC-TV18 that the announcement of minimum support price (MSP) is critical even if it’s coming with a delay.
GRASIM 500325 UBL MS.PRE MS.PRF MS.PRG MS.PRA ASIANPAINT 532478 534816 MS RLNIY ASHOKLEY GRSJY TATAPOWER YYBKY AKLD MS.PRI 532670 MS.PRK 500180 526797 500300 507458 AKLS BHRYY 500820 RELIANCE IDBI 532737 RENUKA RIGD GREENPLY INFRATEL HDFCBANK 500477 YESBANK 500116 IBN UBHOLDINGS 532648 UNBWY GRSXY ICICIBANK EMKAY HDB 532174 TPCL 500400

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...